6 completed. 6 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Completed 6 |
Follow Episodic Migraine: new trials by email Literature Review of Episodic Migraine trials Research Report on Episodic Migraine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention Rimegepant - Migraine, Episodic Migraine | Phase 4 | Completed | Pfizer | 441 | 2022-03-15 | 2025-09-03 |
| Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine Atogepant, Ubrogepant - Episodic Migraine | Phase 4 | Completed | AbbVie | 263 | 2022-03-07 | 2024-10-08 |
| A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine Galcanezumab, Rimegepant, Placebo - Migraine, Episodic Migraine | Phase 4 | Completed | Eli Lilly and Company | 580 | 2021-12-06 | 2024-06-28 |
| Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients AMG334, Oral Prophylactic - Episodic Migraine | Phase 4 | Completed | Amgen | 621 | 2019-05-15 | 2023-11-18 |
| Pilot Study to Collect and Evaluate Data on the Use of IV* Ibuprofen in the Treatment of an Acute Migraine Attack saline placebo, Ibuprofen - Episodic Migraine | Phase 4 | Completed | Thomas Jefferson University | 44 | 2011-06-01 | 2022-09-06 |
| The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache Maxalt, placebo pill, placebo pills - Episodic Migraine | Phase 4 | Completed | Beth Israel Deaconess Medical Center | 76 | 2008-09-01 | 2015-04-09 |
Migraine Disorders (3) · Headache (1) · Hyperacusis (1) · Photophobia (1) · Recurrence (1)
Brain Diseases (3) · Central Nervous System Diseases (3) · Headache Disorders (3) · Headache Disorders, Primary (3) · Nervous System Diseases (3) · Neurologic Manifestations (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Disease Attributes (1) · Ear Diseases (1) · Eye Diseases (1) · Hearing Disorders (1) · Otorhinolaryngologic Diseases (1) · Pain (1) · Pathologic Processes (1)
rimegepant sulfate (2) · Ibuprofen (1) · atogepant (1) · erenumab (1) · galcanezumab (1) · rizatriptan (1) · ubrogepant (1)
AbbVie (1) · Amgen (1) · Beth Israel Deaconess Medical Center (1) · Eli Lilly and Company (1) · Pfizer (1) · Thomas Jefferson University (1)
United States (6) · Argentina (1) · Austria (1) · Belgium (1) · Czechia (1) · Finland (1) · France (1) · Germany (1) · Greece (1) · Ireland (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1) · Portugal (1)
Rami Burstein, PhD (1) · Stephen D. Silberstein, M.D. (1)
PMID 24401940, PMID 34601736, PMID 38526461, PMID 39569702, PMID 41366286
2018 (1)